Abstract

Disclosed herein are compositions and methods for the treatment of hepatitis B infection, including chronic hepatitis B (CHB).

IPC Classes  ?

• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/29 - Hepatitis virus
• A61P 31/20 - Antivirals for DNA viruses
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof

Abstract

The present disclosure provides a crRNA comprising a spacer sequence that is capable of hybridizing to a target RNA sequence, wherein the target RNA sequence is within at least one hepatitis B virus (HBV) transcript, wherein the HBV transcript is selected from the group consisting of pre-core mRNA (pcRNA), pre-genomic RNA (pgRNA), pre-S mRNA, S mRNA, and X mRNA. In some embodiments, there is also provided RNA editing systems comprising the crRNAs disclosed herein, pharmaceutical compositions comprising the crRNAs or RNA editing systems disclosed herein, and methods for the treatment of a HBV infection using the crRNAs or RNA editing systems disclosed herein.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/712 - Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
• A61P 31/20 - Antivirals for DNA viruses
• C12N 9/22 - Ribonucleases

Abstract

Disclosed herein are compositions and methods for the treatment of hepatitis B infection, including chronic hepatitis B (CHB).

IPC Classes  ?

• A61K 39/29 - Hepatitis virus
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/295 - Polyvalent viral antigensMixtures of viral and bacterial antigens
• A61K 39/385 - Haptens or antigens, bound to carriers
• A61P 31/20 - Antivirals for DNA viruses
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof

Abstract

Disclosed herein are compositions and methods for the treatment of hepatitis B infection, including chronic hepatitis B (CHB).

IPC Classes  ?

• A61K 39/29 - Hepatitis virus
• A61K 39/295 - Polyvalent viral antigensMixtures of viral and bacterial antigens
• C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/385 - Haptens or antigens, bound to carriers
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• A61P 31/20 - Antivirals for DNA viruses
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof

Abstract

The technology relates to the use of at least macrocyclic lactone such as ivermectin or moxidectin to inhibit a coronavirus in a subject in order to treat, prevent or reduce the risk of infection by the coronavirus.

IPC Classes  ?

• A61K 31/366 - Lactones having six-membered rings, e.g. delta-lactones
• A61P 31/14 - Antivirals for RNA viruses

Abstract

The technology relates to the use of at least one macrocyclic lactone such as ivermectin or moxidectin to inhibit a coronavirus in a subject in order to treat, prevent or reduce the risk of infection by the coronavirus.

IPC Classes  ?

• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• A61K 31/365 - Lactones

Abstract

The technology relates to the use of at least macrocyclic lactone such as ivermectin or moxidectin to inhibit a coronavirus in a subject in order to treat, prevent or reduce the risk of infection by the coronavirus.

IPC Classes  ?

• A61K 31/366 - Lactones having six-membered rings, e.g. delta-lactones
• A61P 31/14 - Antivirals for RNA viruses

Abstract

The present invention relates to methods of producing a food or malt-base beverage suitable for consumption by a subject with Coeliac's disease. In particular, the present invention relates to methods of producing a food or malt-based beverage with low levels of hordeins. Also provided are barley plants which produce grain that can be used in the methods of the invention.

IPC Classes  ?

• A01H 5/10 - Seeds
• C12C 1/18 - Preparation of malt extract or of special kinds of malt, e.g. caramel, black malt
• C12H 6/02 - Methods for increasing the alcohol content of fermented solutions or alcoholic beverages by distillation
• C12C 12/00 - Processes specially adapted for making special kinds of beer
• A23L 7/109 - Types of pasta, e.g. macaroni or noodles
• A23L 7/20 - Malt products
• A23L 5/20 - Removal of unwanted matter, e.g. deodorisation or detoxification
• A23L 7/10 - Cereal-derived products
• A23L 7/25 - Fermentation of cereal malt or of cereal by malting
• A01H 6/46 - Gramineae or Poaceae, e.g. ryegrass, rice, wheat or maize
• C12G 3/04 - Preparation of other alcoholic beverages by mixing, e.g. for preparation of liqueurs
• C12C 1/125 - Continuous or semi-continuous processes for steeping, germinating or drying

Abstract

Disclosed herein are compositions and methods for the treatment of hepatitis B infection, including chronic hepatitis B (CHB).

IPC Classes  ?

• C07K 7/00 - Peptides having 5 to 20 amino acids in a fully defined sequenceDerivatives thereof
• C07K 7/64 - Cyclic peptides containing only normal peptide links
• C07K 14/02 - Hepadnaviridae, e.g. hepatitis B virus
• C07K 17/00 - Carrier-bound or immobilised peptidesPreparation thereof
• C07K 19/00 - Hybrid peptides

Abstract

The present invention relates to the identification of a profile of antibodies in an individual with chronic hepatitis B (CHB) wherein the existence of this profile is indicative that the individual will achieve or has achieved a functional cure (FC). The present invention further identifies an epitope profile or profile on Hepatitis B virus surface antigen (HBsAg) which represents targets for antibodies which enable a level of clearance to be achieved to reach a functional cure for CHB. Level of occupancy of the epitope profile is indicative that a functional cure will or will not be achieved.

IPC Classes  ?

• G01N 33/576 - ImmunoassayBiospecific binding assayMaterials therefor for hepatitis
• G01N 33/564 - ImmunoassayBiospecific binding assayMaterials therefor for pre-existing immune complex or autoimmune disease

Goods & Services

Downloadable software application using music and guided sessions to promote relaxation, reduction of stress and anxiety, and mental and emotional health Online provision of an internet web based portal using music and guided sessions to promote relaxation, reduction of stress and anxiety, and mental and emotional health; online provision of an internet web based portal for health practitioners in the field of mental and emotional health and relaxation therapy

Abstract

The present invention relates to methods of producing a food or malt-base beverage suitable for consumption by a subject with Coeliac's disease. In particular, the present invention relates to methods of producing a food or malt-based beverage with low levels of hordeins. Also provided are barley plants which produce grain that can be used in the methods of the invention.

IPC Classes  ?

• C12C 1/18 - Preparation of malt extract or of special kinds of malt, e.g. caramel, black malt
• C12H 6/02 - Methods for increasing the alcohol content of fermented solutions or alcoholic beverages by distillation
• A01H 5/10 - Seeds
• C12C 12/00 - Processes specially adapted for making special kinds of beer
• C12G 3/04 - Preparation of other alcoholic beverages by mixing, e.g. for preparation of liqueurs
• C12C 1/125 - Continuous or semi-continuous processes for steeping, germinating or drying
• A23L 5/20 - Removal of unwanted matter, e.g. deodorisation or detoxification
• A23L 7/10 - Cereal-derived products
• A23L 7/109 - Types of pasta, e.g. macaroni or noodles
• A23L 7/20 - Malt products
• A23L 7/25 - Fermentation of cereal malt or of cereal by malting

Abstract

The present invention relates to methods of producing a food or malt-base beverage suitable for consumption by a subject with Coeliac's disease. In particular, the present invention relates to methods of producing a food or malt-based beverage with low levels of hordeins. Also provided are barley plants which produce grain that can be used in the methods of the invention.

IPC Classes  ?

• C12C 5/00 - Other raw materials for the preparation of beer
• C12G 3/04 - Preparation of other alcoholic beverages by mixing, e.g. for preparation of liqueurs
• A01H 5/10 - Seeds
• A23L 1/015 - Removal of unwanted matter, e.g. deodorisation, detoxification (A23L 1/211 takes precedence);;
• A23L 1/10 - containing cereal-derived products
• A23L 1/16 - Types of pasta, e.g. macaroni, noodles
• A23L 1/185 - Malt products (malt products of pulse A23L 1/202; preparation of malt for brewing C12C)
• A23L 1/186 - Fermentation of cereal malt, or of cereal by malting
• C12C 1/18 - Preparation of malt extract or of special kinds of malt, e.g. caramel, black malt
• C12C 12/00 - Processes specially adapted for making special kinds of beer
• C12G 3/12 - by distillation

Abstract

The present invention relates to methods of producing a food or malt-base beverage suitable for consumption by a subject with Coeliac's disease. In particular, the present invention relates to methods of producing a food or malt-based beverage with low levels of hordeins. Also provided are barley plants which produce grain that can be used in the methods of the invention.

IPC Classes  ?

• A01H 1/00 - Processes for modifying genotypes
• A01H 5/00 - Angiosperms, i.e. flowering plants, characterised by their plant partsAngiosperms characterised otherwise than by their botanic taxonomy
• C12N 5/04 - Plant cells or tissues

Abstract

The present invention relates generally to biomarkers of neurological conditions including monitoring disease progression and the clinical severity of symptoms. More particularly, the present invention provides an assay to facilitate diagnosis and monitoring of progression of neurological conditions and treatment response and to identify targets for therapeutic intervention. Kits and assays for diagnosis and identification of medicaments also form part of the present invention.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers

Abstract

The present invention relates generally to diagnostic assays, therapeutic protocols and medicinal predictor model validation. More particularly, genetic tests are provided which determine the suitability of a medicament in the treatment or prophylaxis of a neurological condition. Even more particularly, the present invention provides genetic assays to measure the potential for, or likelihood of, a subject having a positive or adverse treatment response to a neurological medicament. The present invention is particularly useful in the practice of personalized medicine.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor

Abstract

The present invention relates generally to cartilaginous marine animal-derived immunoglobulin-like molecules which bind to a Hepatitis B virus (HBV) antigen or precursor or processed form thereof including a monomeric or multimeric form thereof or an antigenic fragment thereof and their use in therapeutic and prophylactic protocols and diagnostic assays for HBV infection.

IPC Classes  ?

• A61K 35/60 - Fish, e.g. seahorsesFish eggs
• A61K 39/29 - Hepatitis virus
• C07K 16/08 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses

Abstract

The present invention relates to methods of producing a food or malt-base beverage suitable for consumption by a subject with Coeliac's disease, In particula the present invention relates to methods of producing a food or malt-based bevera with low levels of hordeins. Also provided are barley plants which produce grain th can be used in the methods of the invention.

IPC Classes  ?

• C12C 1/00 - Preparation of malt
• A01H 5/00 - Angiosperms, i.e. flowering plants, characterised by their plant partsAngiosperms characterised otherwise than by their botanic taxonomy
• A01H 5/08 - Fruits
• A01H 5/10 - Seeds
• A23L 1/10 - containing cereal-derived products
• A23L 1/185 - Malt products (malt products of pulse A23L 1/202; preparation of malt for brewing C12C)
• A23L 1/202 - Malt products; Fermented malt products (A23L 1/22 takes precedence;malt products of cereals A23L 1/185)
• C12C 1/02 - Pretreatment of grains, e.g. washing, steeping
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 15/09 - Recombinant DNA-technology
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

The present invention relates generally to a method for the treatment of a hemoglobinopathic condition in mammalian subjects such as humans and medicaments useful for same.

IPC Classes  ?

• A61K 38/43 - EnzymesProenzymesDerivatives thereof
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 7/06 - Antianaemics

Abstract

The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. Vaccines and diagnostic assays are also contemplated herein.

IPC Classes  ?

• C12N 15/51 - Hepatitis viruses
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage

Abstract

The present invention relates generally to viral variants exhibiting reduced sensitivity to agents such as nucleoside or nucleotide analogs or other DNA polymerase antagonists and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs or other DNA polymerase antagonists and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus.

IPC Classes  ?

• C12N 15/51 - Hepatitis viruses
• A61K 35/76 - VirusesSubviral particlesBacteriophages
• C12N 7/06 - Inactivation or attenuationProducing viral sub-units by chemical treatment